The global antiviral drugs market size is predicted to grow USD 45.82 billion by 2026 from USD 35.65 billion in 2021. This market is forecasted to be growing at a CAGR of 5.15% during the forecast period.
Antiviral drugs are described as curative or disease-controlling agents against viral infections. These drugs individually attack viruses at different metabolic processes and alter the normal functioning of viral particles. From the past few years, resistance is observed among viruses against different antiviral drugs with an increasing diversity of microorganisms. This challenge leads to the evolution of broad-spectrum antiviral medicines that individually attack viruses at specified targets such as DNA Polymerase, NS3 Protease, & Reverse Transcriptase. These drugs are used to prevent or cure different viral infections such as HIV/AIDS, Hepatitis, influenza, and other viral infections.
Anti-virus drugs are a class of medicine that kills a virus such as HIV, chickenpox, papilloma, hepatitis B and C viruses, herpes viruses, influenza A and b viruses, or that suppress virus ability to replicate. Most anti-viruses target specific types of viruses. Moreover, broad-spectrum anti-virus drug is effective against an extensive range of virus. Unlanti-viral number of antibiotics, antiviral drugs do not kill their target pathogen. The global antiviral drug market showed consistent growth in the pharmaceutical industry and is predicted to continue the growing trend in the coming years due to the rise in awareness in the people and better efficiency of the developed drug. The significant patents in anti-virus drugs are Tenofovir, Tamiflu, Relenza, and Telbivudine, Sustivahave changed the anti-virus face.
Y-O-Y growth in the incidence of viral infections is majorly accelerating the growth of the global antiviral drugs market.
The global antiviral drugs market is primarily driven by virus infections such as influenza, respiratory syncytial virus, hepatitis, and HIV. An increase in research and development activities and innovation of new formulation, including vaccine and various therapy, is anticipated to drive the market's growth. According to the report of UNAIDS, there were 37.9 million people globally who are suffering from HIV/AIDS in 2019. In that, 36.2 million people are adults, and 1.7 million were children, while 770000 people died from this disease.
Additionally, growing public awareness, boost in the R &D segment, increasing interest to support the development of novel antiviral drugs, the existence of a well-established supply chain further lavish the growth of the global antiviral drugs market.
Furthermore, the rise in healthcare infrastructure spending capability in developed and developing countries, increasing dilation of life-threatening virus disease, and people awareness are fuelling the market growth. As late-stage pipeline drugs are anticipated to hit the market, this further supports the antiviral drugs market growth.
The high cost involved in developing drugs and an increase in the demand for different medicine like naturopathy and homeopathy-viral is degrading the market growth of antiviral medication. In addition to this high risk of failure, the high cost of research and therapy and stringent government activities hamper the market's growth. Increasing the use of natural products is the critical challenge faced by the market.
Furthermore, increasing preventive measures and the availability of vaccines for various viral diseases is hampering the antiviral drugs market growth to some extent.
Impact of COVID-19 on the global anti-viral drugs market:
Millions of people across the world are affected by the coronavirus. This pandemic has put massive pressure on medicine safety stocks. Healthcare providers such as doctors and nurses use every possible tool to treat the COVID-19 and other related infections. It results in tremendous pressure on several medicines, including antiviral drugs. Similarly, the pressure on the system is substantially growing with increased demand from patients and governments for crucial medicines. Scientists and researchers are relentlessly working to develop an investigational antiviral compound to treat the SARS-CoV-2 virus.
Antiviral composites show activity against SARS-CoV-2 in preclinical Screenings. The companies are collaborating (ex: Pfizer and BioNTech) to develop the COVID-19 vaccine due to the rising demand. The companies predict the selection of lead COVID-19 Vaccine since January 2020; they are expected to form the lead vaccine by September 2020, and the first batch of COVID-19 vaccine could be available for emergency use approval in early 2021. Many huge companies are expanding their global manufacturing capacity. So, the additional capacity will contribute to the fast production of the antiviral vaccine, and they can supply more than one billion doses of an effective vaccine globally.
Recently, companies have brought affordable vaccines for the public about the vast demand not for profit but emergency pandemic use. These drugs will give potential immunity to the patients. Governments are giving approvals for the fast scale-up; it can also help them reopen economies. Still, there are no potential treatments and vaccines for Covid-19; major companies are trying to use existing drugs to fight against the novel coronavirus. The use of specific antiviral drugs for Covid-19 treatment contributes to the growth of the global antiviral drugs market. Moreover, any of these drugs under trials express further promising results in treating the Covid-19 infection.
Market Size Available
2021 to 2026
2021 to 2026
By Application, Target, End Users, and Region
Various Analyses Covered
Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter's Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities
North America, Europe, Asia Pacific, Latin America, Middle East & Africa
This research report on the global antiviral drugs market segmented and sub-segmented based on the application, target, end-users, and region.
Antiviral Drugs Market - By Application:
Based on application, the HIV/AIDS and the Hepatitis segments were together accounted for the highest market share in the global antiviral drugs market in 2019 and are predicted to continue their domination throughout the forecast period. The growth is primarily driven due to the standard increase of infectious diseases that are transmitted.
Antiviral Drugs Market - By Target:
Based on the target, the reverse transcriptase segment is projected to perform well during the forecast period. This segment is said to be influencing the antiviral drugs market for the forthcoming years due to the efficacy in averting or slowing down viral infections.
Antiviral Drugs Market - By End Users:
Based on the End-User, the hospital's segment was accounted for the largest share in 2019 and forecasted to grow at the highest CAGR during the forecast period. The growth of the segment is attributed to many patients, along with their admissions, which are the factors responsible for the growth of the antiviral drugs market.
Antiviral Drugs Market - By Region:
Regionally, the North American antiviral drugs market is forecasted to be the most influencing region in the global antiviral drugs market and accounted for more than 34.0% of the share in the global market in 2020. The North American market size is estimated to reach USD 10.95 billion by 2024, with a CAGR of 4.47% over the forecast period. The factors responsible for the growth of the market in this region include an emergency of the critical situation of diseases and a standard increase of infectious diseases across the globe. In this region, the United States is the leading market.
The Europe market stands second in leading highest shares in the global antiviral drugs market, followed by North America. European antiviral drugs market size is projected to grow at a CAGR value of 4.98% over the forecast period. Factors such as new vaccines coming into the market by the key players and common infectious diseases fuel market growth. The UK leads the market in this region.
The Asia-Pacific market is expected to have fast growth throughout the period with a CAGR value of 6.12% from 2019 to 2024. China is the most lucrative country in the Asia Pacific antiviral drugs market, obtaining majority shares in the market in 2019 due to increasing knowledge in public and the launch of new products. Japan is next to China in showcasing a healthy CAGR.
The Latin American antiviral drugs market size is estimated to worth USD 5.06 billion by 2024. The governments of the Latin America region are working on introducing new antiviral drugs for those who are suffering from infectious diseases like Hepatitis C, also HIV/AIDS. These factors are responsible for market growth in Latin America.
The Middle East & Africa region is estimated to showcase a CAGR of 5.07% during the forecast period. Factors such as an increase in healthcare expenditure, rising occurrence of viral infections, and utilization of natural medicines are majorly propelling the market growth in this region.
KEY MARKET PARTICIPANTS:
Companies leading the global antiviral drugs market profiled in this report are Johnson & Johnson (USA), Novartis International AG (Switzerland), Roche Holding AG (Switzerland), Pfizer (USA), Merck and Co. Inc. (USA), GlaxoSmithKline plc (United Kingdom), AstraZeneca AB (United Kingdom), Gilead Sciences (USA) and Abbott Laboratories (USA).
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.7 Y-o-Y Growth Analysis, By Application
5.1.8 Market Attractiveness Analysis, By Application
5.1.9 Market Share Analysis, By Application
5.2.2 DNA polymerase
5.2.3 NS3 Protease
5.2.4 Reverse transcriptase
5.2.6 Y-o-Y Growth Analysis, By Target
5.2.7 Market Attractiveness Analysis, By Target
5.2.8 Market Share Analysis, By Target
5.3 End Users
5.3.3 Research Institutes
5.3.4 Laboratory Centers
5.3.5 Y-o-Y Growth Analysis, By End Users
5.3.6 Market Attractiveness Analysis, By End Users
5.3.7 Market Share Analysis, By End Users
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.4 Market Attractiveness Analysis
6.1.5 Market Share Analysis
6.2 North America
6.1.2 United States
6.3.6 South Korea
6.5 Latin America
6.4.5 Rest of Latin America
6.6 Middle East & Africa
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Novartis International AG
8.3 Roche Holding AG
8.5 Merck and Co. Inc
8.6 GlaxoSmithKline plc
8.7 AstraZeneca AB
8.8 Gilead Sciences
8.9 Abbott Laboratories
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures